These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 7693430

  • 1. Current status of dopamine agonists in Parkinson's disease management.
    Montastruc JL, Rascol O, Senard JM.
    Drugs; 1993 Sep; 46(3):384-393. PubMed ID: 7693430
    [Abstract] [Full Text] [Related]

  • 2. Dopamine agonists and Parkinson's disease.
    Burton K, Calne DB.
    Clin Neurol Neurosurg; 1984 Sep; 86(3):172-7. PubMed ID: 6091965
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacology of dopamine agonists in Parkinson's disease.
    Lange KW.
    Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Nov; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 5. Dopaminergic agonists in the treatment of Parkinson's disease.
    Goetz CG, Diederich NJ.
    Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
    [Abstract] [Full Text] [Related]

  • 6. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
    Agid Y, Barroche G, Bonnet AM, Javoy-Agid F, Kato G, Lhermitte F, Pollak P, Signoret JL.
    Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
    Nyholm D.
    Clin Pharmacokinet; 2006 Jun; 45(2):109-36. PubMed ID: 16485914
    [Abstract] [Full Text] [Related]

  • 8. Dopamine agonists in Parkinson's disease.
    Calne DB, Burton K, Beckman J, Martin WR.
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):221-4. PubMed ID: 6231979
    [Abstract] [Full Text] [Related]

  • 9. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL, Rascol O, Senard JM.
    Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
    [Abstract] [Full Text] [Related]

  • 10. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN.
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
    Mov Disord; 2002 Jul; 17 Suppl 4():S53-67. PubMed ID: 12211141
    [No Abstract] [Full Text] [Related]

  • 13. [Apomorphine in off state--clinical experience].
    Rudzińska M, Szczudlik A.
    Neurol Neurochir Pol; 2007 Jul; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
    Calne DB.
    J Neural Transm Suppl; 1999 Jul; 56():185-92. PubMed ID: 10370912
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM, Heuser IJ, Baronti F, Giuffra M, Conant K, Davis TL, Chase TN.
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [Abstract] [Full Text] [Related]

  • 20. DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.
    Mov Disord; 2002 May; 17 Suppl 4():S79-82. PubMed ID: 12211145
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.